OR WAIT 15 SECS
Montreal, Canada and Madison, NJ-Bausch + Lomb has acquired an option to license MIM-D3 and developed by Mimetogen Pharmaceuticals Inc. an investigational compound currently in Phase II development for the treatment of dry eye syndrome (DES).
MIM-D3 has the potential to be the first in a new class of agents called TrkA agonists, according to Mimetogen. MIM-D3 stimulates the production of mucin, vital for the protection and overall health of the ocular surface. In addition, MIM-D3 may have additional benefits than currently available dry eye therapies including the potential to improve neural function, which may improve corneal sensitivity and integrity.
Phase II study results for MIM-D3 demonstrated that the use of MIM-D3, dosed bid, results in consistent improvements across multiple dry eye signs and symptoms with no safety or tolerability issues. A Phase III study is scheduled to begin before the end of 2013, which will be conducted by Ora Inc.